Ranjit Nair

Ranjit Nair is an Associate Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center. He specializes in hematological malignancies, with a focus on lymphoid neoplasia, leukemia, and cellular immunotherapy. His research centers on optimizing CAR T-cell therapy for relapsed/refractory B-cell lymphomas, including predictive biomarkers for cytokine release syndrome and neurotoxicity, as well as combination strategies with targeted agents such as ibrutinib and acalabrutinib. His recent work has been published in Blood, JAMA Network Open, and Blood Advances, and he has investigated cytokine storm mechanisms across CAR-T therapy, COVID-19, and hemophagocytic lymphohistiocytosis. He also leads clinical trials exploring novel frontline regimens for high-risk mantle cell lymphoma.